Endoscopic bariatric therapies for obesity: a review.
Dominic A StaudenmannZhixian SuiPayal SaxenaArthur J KaffesGeorge MarinosVivek KumbhariPatrick AepliAdrian SartorettoPublished in: The Medical journal of Australia (2021)
▪ Obesity is reaching pandemic proportions globally, with overweight or obesity affecting at least two-thirds of Australian adults. ▪ Bariatric surgery is an effective weight loss strategy but is constrained by high resource requirements and low patient acceptance. ▪ Multiple endoscopic bariatric therapies have matured, with well established and favourable safety and efficacy profiles in multiple randomised controlled trials (RCTs), and are best used within a multidisciplinary setting as an adjuvant to lifestyle intervention. ▪ Three types of intragastric balloon are currently in use in Australia offering average total weight loss ranging from 10% to 18%, with others available internationally. ▪ Endoscopic sleeve gastroplasty produces average total weight loss of 15-20% with low rates of severe complications, with RCT data anticipated in December 2021. ▪Bariatric and metabolic endoscopy is rapidly evolving, with many novel, promising therapies currently under investigation.
Keyphrases
- weight loss
- bariatric surgery
- roux en y gastric bypass
- ultrasound guided
- gastric bypass
- obese patients
- weight gain
- randomized controlled trial
- glycemic control
- early stage
- sars cov
- type diabetes
- metabolic syndrome
- electronic health record
- risk factors
- insulin resistance
- big data
- endoscopic submucosal dissection
- physical activity
- drug induced
- deep learning
- artificial intelligence
- data analysis